StockWatch
·
RELAXO · Q2 FY27 · PREVIEW

Growth continuity tested amid factory capacity constraints

Relaxo reports Q2 results on Nov 13 with the Street watching whether 7-8% revenue growth can persist despite ongoing factory renovation and reduced manufacturing capacity. Margins and volume momentum are the key gauges.

Q2 FY27 resultsRELAXORELAXO FOOTWEARS LTD.-$10 Nov 2026 · 3 min read

Relaxo Footwears reports Q2 FY27 results on November 13 after delivering a solid start to the fiscal year. In Q1 (ended Jun 2026), revenue grew 7.7% YoY to ₹705 crores with net profit rising 12.4% to ₹54.94 crores. The full-year FY2027 guidance implies 10.4% revenue growth and 16.7% EPS expansion. But Q2 arrives against a backdrop of factory modernization—the company in August reassessed total manufacturing capacity down to 9.1 lakh pairs per day from 10.5 lakh, citing ongoing reconstruction of older plants. The Street's focus will be on whether Relaxo can sustain mid-single-digit growth momentum and defend margins as utilization pressure persists.

The on-plan expectation

Revenue

~₹700–750 Cr

to sustain +7 to +8% YoY growth; Q1 was ₹705 Cr, so flat to mid-single digit momentum indicates on-track

EBITDA growth

~8–9%

Q1 EBITDA rose 8.8% YoY; key watch is whether lower capacity utilization pressures margin %

Net margin resilience

Watch

Q1 net profit +12.4%, outpacing revenue +7.7%; sustainability amid capex and lower capacity is the swing factor

A strong Q2 print would show revenue growth >8% with EBITDA margins stable or improved despite the capacity headwind—evidence that pricing power and cost control offset lower utilization. A weak print would be revenue growth 100 bps, signaling that demand is softer than the full-year guidance implies or that capex-related disruption is heavier than guided.

On track with guidance?

Yes, if growth stays near 7–8% for Q2. Q1's 7.7% implies momentum—even with factory renovation headwinds, management's 10.4% full-year growth target hinges on Q3–Q4 acceleration once capacity ramp resumes. The capacity reassessment down (not up) is the risk signal: if demand softens, lower utilization becomes a drag. If demand is robust, Relaxo should be able to boost production once the renovation completes, driving back-half acceleration and reaching full-year guidance. Analysts are pricing in 10–11% growth; Q2 will test whether that's real.

What the Street says

Since last quarter: filings and corporate actions

Key filings and events post-Q1 (Aug–Nov 2026)

Oct 23

Event

26% stake in Clean Max MUOI (renewable energy SPV)

Impact / Note

Strategic pivot to ESG / renewable energy; capital deployment shift; longer-term margin upside if renewable costs decline

Oct 5

Event

Energy Supply & Investment Agreement with Clean Max

Impact / Note

Caps energy costs over medium term; supporting margin defense amid inflationary pressures

Sep 30

Event

CS & Compliance Officer Ankit Jain resigned

Impact / Note

Routine mgmt transition; no governance red flags; successor TBD

Aug 31

Event

42nd AGM (Sep 24), Annual Report filed; BRSR filed for FY26

Impact / Note

Routine governance; no material changes flagged in shareholding or board composition

Aug 13

Event

Capacity reassessment: 10.5L → 9.1L pairs/day

Impact / Note

Factory renovation/modernization; near-term capacity headwind; medium-term upside if capex drives productivity

No material insider/promoter activity or pledges flagged. Ownership remains stable: FII 3.11%, DII 9.67%, promoter 71.27% (as of Q1 FY27). The renewable energy investment is strategic, not a distress capital-raise. The capacity reduction is temporary and deliberate—not a demand collapse—so long as the Q2 revenue trajectory holds.

What to watch on result day

Three gauges for the Nov 13 print
  • 1 · Revenue growth momentum

    Can Relaxo sustain >7% YoY growth with 9.1L pairs/day capacity? If Q2 revenue is ₹700–750 Cr (on-plan), it validates the 10.4% full-year guidance. If <₹680 Cr, watch management's commentary on demand and back-half acceleration.

  • 2 · EBITDA margin

    The critical line. Q1 EBITDA margin (~14% implied) should be defended or improved in Q2. Expansion >100 bps would signal pricing power and cost discipline; contraction >100 bps would raise questions about demand softness or capex cost overruns.

  • 3 · Capacity ramp and capex guidance

    Management must clarify the factory renovation timeline and expected capacity recovery. If capex is ramping to ₹50+ Cr/quarter, FCF could face pressure through FY27 even if bottom-line growth accelerates. Watch for updates on when 10.5L pairs/day capacity returns.

Relaxo's Q2 is a test of growth durability amid self-imposed capacity constraints and a macro slowdown in consumer discretionary demand. The company delivered solid Q1 momentum (7.7% growth, margin resilience), and the Street's 10.4% full-year estimate implies confidence in back-half recovery. But the capacity reduction, while temporary, leaves no room for demand disappointment—Q2 revenue must stay in the ₹700–750 Cr band and margins must hold to validate guidance. Promoter control (71.27%) and the renewable energy pivot suggest management confidence in the medium-term narrative (lower energy costs, productivity capex). Watch the absolute revenue number, EBITDA margin trends, and any color on when full capacity returns.

Informational and educational content only. Not investment advice.